Einmal drehen bitte.
NanoMab and gate startup OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals NanoMab Technology Limited, a privately held biopharmaceutical company focussing on precision cancer therapies, today announced that it had signed Heads of Terms with OncoBeta® GmbH, a supplier … Weiterlesen
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer of the gate-startup to be produced in Australia OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers and the Australian Nuclear Science and Technology Organisation (ANSTO), are pleased to announce that they have signed a Letter of … Weiterlesen
OncoBeta® has recently been presented with the CV Magazine’s Corporate Excellence Award for the Most Compassionate Skin Cancer Therapy Provider in 2019. The Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs) residents at the business incubator gate in Garching, Munich. CV Magazine’s annual Corporate Excellence Awards are handpicked by … Weiterlesen